Focus: Spectrum Dynamics is a public-stage biotech company specializing in advanced imaging technologies, headquartered in Sarasota, FL with 201-500 employees. The company generates 100% of revenue from ROLVEDON (eflapegrastim-xnst), a peak-lifecycle granulocyte colony-stimulating factor (G-CSF) product.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Spectrum Dynamics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Only approved revenue-generating product; accounts for 100% of company revenue, indicating both strategic importance and concentration risk.
Help build intelligence for Spectrum Dynamics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Spectrum Dynamics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-loss-of-exclusivity chemotherapy with ANDA approval; likely generating minimal revenue or being partnered.
Anti-CD20 radioimmunotherapy approaching loss of exclusivity; likely generating declining revenues.
NDA-approved fluorouracil formulation approaching exclusivity cliff; minimal revenue contribution expected.
2 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Evaluation of 9-Minute Dual-Energy Peak Time-Reduced 360° CZT Total-Body [(177)Lu]Lu-PSMA SPECT/CT Imaging with Comparisons to [(68)Ga]Ga-PSMA PET.
A deep-learning noise reduction algorithm outperforms the spatial filters previously required for bone SPECT on a high-speed whole-body 360° CZT-camera.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo